![](https://investorshub.advfn.com/uicon/119080.png?cb=1710361148)
Thursday, March 18, 2010 11:40:52 PM
Industry : Medical Instruments & Supplies
Employees : 87
Exchange : Other OTC Issues
Aksys, Ltd. (Aksys) was established to provide hemodialysis products and services for patients suffering from end-stage renal disease (ESRD), commonly known as chronic kidney failure. The Company has developed an automated personal hemodialysis system, known as the Aksys Personal Hemodialysis (PHD) System (the PHD System), which is designed to enable patients to perform frequent hemodialysis at alternate sites (such as their own homes), and to thereby improve clinical outcomes, reduce total ESRD treatment costs and enhance the quality of life of patients. The Company’s target market is the ESRD treatment market. A healthy human kidney continuously removes waste products and excess water from the blood. ESRD is a slow, progressive loss of kidney function caused by inherited disorders, prolonged medical conditions, such as diabetes and hypertension, or the long-term use of certain medications. ESRD is irreversible and lethal if untreated.
The information is not intended as investment advice, as an on offer or solicitation of an offer to sell or buy. Subscribers and users of the free service assume the entire cost and risk of any trading they choose to undertake.
Element79 Gold Corp Appoints Warren Levy to Board of Directors • ELMGF • Aug 28, 2024 9:51 AM
Integrated Ventures Announces Strategic Entry Into Health & Wellness Industry with Focus on GLP-1 Products • INTV • Aug 28, 2024 8:30 AM
ELEMENT79 ANNOUNCES UPLISTING TO OTCQB VENTURE MARKET • ELMGF • Aug 26, 2024 10:03 AM
North Bay Resources Announces Gold Assays up to 2.2 Ounces per Ton, Fran Gold Project, British Columbia • NBRI • Aug 26, 2024 10:00 AM
PickleJar Unveils Latest Venue Managed Services Innovations in Upcoming Webinar • PKLE • Aug 23, 2024 1:11 PM
Element79 Gold Corp Provides Update on Nevada Portfolio • ELMGF • Aug 23, 2024 8:00 AM